Stories about Medizin, Gesundheit
- One documentmore
Press release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
One documentmoreGerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
Düsseldorf (ots) - At today’s Capital Markets Day, Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted ...
One documentmore- 3
Press release: STADA starts work on >EUR50m facility to strengthen European medicines supply
One documentmore Press release: Stéphane Jacqmin joins STADA from Sanofi and becomes Head of Emerging Markets
One documentmorePress release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
One documentmore- 5
Press Release - hubergroup India supports rural areas with medical vans
One documentmore Gerresheimer reports double digit growth in revenue and earnings for the third quarter
Duesseldorf (ots) - - Organic revenue growth of 17.4% in the third quarter supported by continued strong demand for High Value Solutions - Organic adjusted EBITDA up 13.3% - Gerresheimer firmly on track to deliver on FY 2022 guidance Gerresheimer AG, a leading provider of healthcare & beauty solutions ...
One documentmorePress release: STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease
STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease - Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A ...
One documentmorePress release: Strong in-market performance leads STADA to double-digit growth
Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...
One documentmore- 6
Press release: Aurubis plants in Hamburg and Lünen receive internationally recognized Copper Mark quality seal
One documentmore Press release: STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy - The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a ...
One documentmoreGerresheimer on track to deliver record financial year 2022 after solid second quarter
One documentmoreSTADA Health Report 2022: Europe experiencing worsening health conditions
STADA Health Report 2022: Europe experiencing worsening health conditions - Self-assessed burnout rates at all-time high; stress levels have increased; more than one in three are struggling with sleep; appreciation for healthcare systems decreases after Covid high - STADA Health Report 2022: ...
One documentmore- 3
Press release: Maintenance shutdown at Aurubis plant in Hamburg completed successfully
One documentmore Press release: STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab - Offers a comprehensive range of presentations to the EU adalimumab biosimilars market - Adalimumab marks the first molecule ...
One documentmore- 3
Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit
One documentmore Press release: STADA set to expand Specialty portfolio after positive CHMP opinion on Kinpeygo orphan medicine for IgA nephropathy
STADA set to expand Specialty portfolio after positive CHMP opinion on KinpeygoTM orphan medicine for IgA nephropathy - CHMP within the European Medicines Agency issues positive opinion on KinpeygoTM, a novel oral formulation of budesonide, for ...
One documentmore- 2
Press release: Investment in the future: major planned maintenance shutdown at Aurubis' plant in Hamburg
One documentmore Innovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio
One documentmoreBrenntag announces new agreement with Corbion for Animal Nutrition in Belgium, The Netherlands and France
One documentmoreBrenntag’s Larry Davis on serving major trends in the Nutrition industry
One documentmoreBrenntag’s Pharma section signs exclusive agreement for health-promoting product line Akovita ELIP in EMEA
One documentmoreBrenntag invests in its Animal Nutrition production unit in Kędzierzyn-Koźle, Poland
One documentmore- 4
RTL Donation Marathon: Einhell offers support to children suffering from cancer
One documentmore - 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
One documentmore - 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
One documentmore - 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
One documentmore AM plays to its strengths in the medical field
One documentmore- 2
Lindis Biotech develops immunotherapy against bladder cancer
One documentmore